Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Credit agreement amended June 22, 2026 to permit planned notes issuance.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Credit agreement amended June 22, 2026 to permit planned notes issuance
- Minimum Consolidated EBITDA covenant reduced to $100 million through March 31, 2027
- EBITDA covenant increases to $150 million for subsequent four-quarter periods
- Amendment provides financing flexibility while introducing tighter future operating-performance requirements
Item 8.01 · Other Events
- Proposed $550 million convertible senior notes due 2031, creating substantial potential financing and dilution exposure
- Additional $82.5 million notes option available to initial purchasers during a 13-day period
- Rule 144A private placement limited to qualified institutional buyers, avoiding immediate public registration
- Proceeds and conversion terms require review in Exhibit 99.1 for capital allocation and shareholder dilution implications
Item EX-99.1 · Exhibit EX-99.1
- Proposed $550 million convertible senior notes due September 15, 2031, with a potential $82.5 million upsizing option
- Interest rate and conversion terms unset, leaving future financing cost and dilution uncertain until pricing
- Up to $75 million earmarked for concurrent share repurchases, potentially offsetting conversion dilution and supporting near-term share price
- Convertible hedges expected to reduce note-related dilution, while warrants could dilute shares above their strike price
- Remaining proceeds target general corporate purposes, including potential investments and previously announced Xoma Royalty acquisition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.